Today: 29 January 2026
Subscribe
Browse Category

Pharma Industry News 29 September 2025 - 15 October 2025

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump Nasdaq. The very next day (Oct 8) the stock rebounded sharply, jumping roughly 16% to ~$6.08 ts2.tech. This put RXRX near the middle of its 52-week trading range (about $3.97–$10.87)…
15 October 2025
····
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Latest News & Developments On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share (≈$13.00 total) Marketscreener Reuters. This values Astria at roughly $920M equity and $700M enterprise Stocktitan. The Boards…
14 October 2025
····
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease Newamsterdampharma. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion…
11 October 2025
··
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech Fiercebiotech; MarketBeat and DirectorsTalk analyst surveys Marketbeat Directorstalkinterviews; Economic Times deal summary Indiatimes Indiatimes; Business Wire legal alert Businesswire Businesswire; and TradingView market data Marketbeat Tradingview.…
9 October 2025
····
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 Insidermonkey, putting it near the middle of its volatile 52-week range ($3.97 – $10.87) ts2.tech. For context, RXRX had traded in the double-digits when…
9 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one…
6 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highs Marketbeat.…
6 October 2025
···
1 … 6 7 8

Stock Market Today

  • Asian Shares Dip, Gold Surges Over 4% Following Fed Rate Pause
    January 28, 2026, 11:28 PM EST. Asian markets edged mostly lower Thursday as investors adopted a cautious stance after the Federal Reserve held its key interest rate steady. Fed Chair Jerome Powell signaled rates are "in a good place" for now. Gold surged over 4% to $5,520 an ounce, marking a sharp safe-haven move. Tokyo's Nikkei slipped 0.2%, weighed by mixed tech earnings despite a 6.7% jump in Advantest. South Korea's Kospi hit a fresh record, led by strong chipmaker SK Hynix gains. Jakarta's JSX plunged 7.4% after MSCI flagged Indonesian market risks. In U.S. markets, the S&P 500 was flat with gains from Seagate and Nvidia offsetting Apple weakness. The dollar weakened against the yen, easing to 152.99 yen amid no signs of U.S. currency intervention. Treasury yields held steady at 4.24% on the 10-year, reflecting mixed inflation and economic signals.
Go toTop